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Abstract 
 
Antidepressants are one of the most commonly prescribed drugs in America, with researchers 
reporting one in six Americans take some form of psychiatric drugs-mostly antidepressants 
(NBC News, 2016). Antidepressants are often present in combination with other drugs in 
suicides and drug-related deaths, so a sensitive and specific method to detect and quantify 
antidepressants is necessary. We developed a method for the detection and quantification of 18 
different antidepressants in whole blood, with a range of 2.5-900 ng/mL and LOQ of 2.5 ng/mL. 
Three hundred uL of blood was used and the analytes were extracted using solid-phase extraction 
and analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS), monitoring 
two transitions per analyte. The method was validated and applied to 10 positive authentic 
samples, and blind proficiency testing was additionally performed to test the method’s ability to 
successfully quantitate the analytes.  
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Introduction  
Antidepressants are a class of drugs commonly prescribed for the treatment of psychiatric 
patients suffering from clinical depression as well as anxiety disorders. According to the Center 
for Disease Control and Prevention (CDC, 2017), about one in eight Americans aged 12 and over 
reported taking antidepressants in the previous month, and antidepressant use increased nearly 65% 
over a 15-year time frame, since 1999 (NBC News, 2016). There are different types of 
antidepressants, based on their mechanisms of action (Mayoclinic, 2017); these are tricyclic 
antidepressants (amitriptyline), selective serotonin reuptake inhibitors (fluoxetine, citalopram, 
paroxetine, sertraline), serotonin noradrenaline reuptake inhibitors (venlafaxine), noradrenergic 
and specific serotonergic antidepressants (mirtazapine) (Heck and Macqueen, 2012), as well as 
active metabolites (desmethylvenlafaxine). From the various categories of antidepressants listed 
above, tricyclic antidepressants (TCA) were the first class of antidepressants to be widely used to 
treat depression. TCAs impose their therapeutic effects by inhibiting presynaptic reuptake of 
norepinephrine and serotonin in the central nervous system (Mayoclinic, 2017). However, they 
were found to induce side effects such as seizures, cardiac toxicity, and risk overdose (Antipolis, 
2010). Therefore, it has been recommended that new antidepressants such as selective serotonin 
reuptake inhibitors (SSRIs), which increase serotonin levels in the brain by blocking its reuptake 
(Andrews and Pinder, 2001), should be the first-line option when drug therapy is indicated for a 
depressive episode (Cipriani et al., (2010). These newer antidepressants are considered safer to 
use since they have a broader therapeutic range compared to TCAs (Marken and Munro, 2000).  
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Misuse of these drugs can lead to impairment as well as unwanted side effects and drug-drug 
interactions. Since most large-scale surveys generally do not include antidepressant misuse as a 
category of substance abuse that is specifically measured, it is difficult to fully characterize the 
prevalence of this issue. However, a few studies (Evans and Sullivan, 2014; Taieb et al., 2004) 
have been reported on certain antidepressants that have played a role in antidepressant misuse 
and overdose, such as bupropion. Bupropion, which acts via dual inhibition of norepinephrine 
and dopamine reuptake, has been reported to induce stimulant and cocaine-like, euphoric effects; 
a sensation of feeling “high” by those abusing bupropion (Evans and Sullivan, 2014) When 
bupropion is crushed and ingested through the nasal cavity avoiding the first-pass metabolism, 
higher bioavailability occurs, heightening the misuse potential (Hilliard et al., 2013). Similarly, 
the metabolite of trazodone, m-chlorophenylpiperazine has recently entered the illicit drug 
market, because it mimics the psychoactive effects of 3,4-methylenedioxymethamphetamine, 
MDMA (Wille et al., 2005). Although antidepressants are considered to be relatively safe in 
regard to drug dependence and withdrawal symptoms compared to other drugs, case studies have 
been reported of individuals exhibiting severe withdrawal symptoms after pausing intake of 
particular antidepressants such as fluoxetine (Taieb et al., 2004).  
 
Antidepressants are often present in addition to other types of drugs, in suicides and drug-related 
deaths. Due to the fact that they are commonly used in combination to other drugs, it is important 
to be able to determine if any unwanted drug-drug interactions occurred when a drug-related 
crime has happened. There have been reported cases of fatal overdoses involving combinations 
of venlafaxine and alcohol (Evans and Sullivan, 2014), as well as synergistic effects of opiates 
and TCAs when found together in postmortem cases (Hepburn et al., 2005). In each case of 
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suicide and drug-related death autopsied in the Institute of Forensic Medicine, Munich during the 
years 2001–2005, a toxicological investigation on anti-depressants (AD) was performed. It was 
found that antidepressants were found in almost all of the cases, with TCAs present in 79.63% of 
all narcotic drug deaths and 62.87% of all suicides. Doxepin was present in 51.5% of all narcotic 
drug deaths and 32.41% of all suicide cases (Drasch et al., 2008). Antidepressants are also 
commonly found in drug facilitated sexual assaults due to some of their sedative side effects 
(Hurley et al., 2006). According to the Society of Forensic Toxicologists (“Society of Forensic 
Toxicologists,” 2019), common antidepressants found in DFSAs are Elavil (amitriptyline) and 
Zoloft (sertraline). Therefore, it is crucial that a large variety of antidepressants are able to be 
detected and quantified easily in the forensic laboratory. 
 
Several methods for the determination of antidepressants in various matrices, such as blood, 
serum, and plasma, have been previously published (Montenarh et al., 2014; Nielson and 
Johansen, 2012; Castaing et al., 2007; Wille et al., 2005). Screening and confirmation is mostly 
done by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-MS (LC-
MS) procedures (Kraemer and Paul, 2007). Antidepressants in blood, serum, and plasma have 
been extracted using liquid-liquid extraction and quantified by liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) in a multi-analyte screening of 33 different antidepressants 
(Montenarh et al., 2014) and in a smaller screen of 8 antidepressants and 5 different metabolites 
(Castaing et al., 2007). Antidepressants in blood have also been analyzed using liquid-liquid 
extraction and an ultra-performance liquid chromatography-tandem mass spectrometry method 
(Nielson and Johansen, 2012). Thirteen antidepressants have also been extracted and quantified 
using solid phase extraction and gas chromatography-mass spectrometry (Wille et al., 2005).  
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In this project, a LC-MS/MS method with solid-phase extraction was optimized and validated for 
the detection and quantification of 18 antidepressants in whole blood. The method was then 
applied to authentic donor samples. The 18 antidepressants are shown below. 
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Materials and Methods 
The antidepressants that were purchased for analysis were amitriptyline, bupropion, citalopram, 
clomipramine, cyclobenzaprine, desipramine, o-desmethylvenlafaxine, doxepin, duloxetine, 
fluoxetine, imipramine, mirtazapine, nortriptyline, paroxetine, sertraline, trazodone, trimipramine, 
and venlafaxine obtained from Cerilliant (TX, USA) in concentrations of 1 mg/mL in 1 mL 
methanol. The internal standards that were used were amitriptyline-d3, bupropion-d9, citalopram-
d6, desipramine-d3, doxepin-d3, duloxetine-d3, fluoxetine-d6, imipramine-d3, nortriptyline-d3, 
paroxetine-d6, sertraline-d3, and venlafaxine-d6 also obtained from Cerilliant (TX, USA) in 
concentrations of 100 ug/mL in 1 mL of methanol, except for Doxepin-d3 which had a 
concentration of 1 mg/mL in 1 mL of methanol. Ten positive authentic blood samples were 
obtained from the Cordant Laboratory. Negative blood samples from the blood bank provided by 
Cordant were used for the method development and validation. 
 
Preparation of Working Solutions 
Four intermediates of the 18 drug samples with concentrations of 100,000 ng/mL, 10,000 ng/mL, 
1,000 ng/mL, and 100 ng/mL in methanol were prepared. One mL of each of the nine drugs were 
added to a 10 mL volumetric flask and dried down in the concentrator until only about a third of 
the volume was left. One mL of the other four drugs were added and dried down to a third of the 
volume. Finally, 1 mL of the remaining five drugs were added. Then, the flask was filled to 10 
mL with methanol and the contents were transferred to an amber vial and labeled ‘100,000 
ng/mL intermediate’. Next, a 10,000 ng/mL intermediate was prepared by taking 1 mL of the 
100,000 ng/mL intermediate and adding it to a 10 mL volumetric flask and filling it to the 10 mL 
line with methanol. The contents were transferred to another amber vial. The 1,000 ng/mL 
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intermediate was prepared by doing the same with 1 mL of the 10,000 ng/mL intermediate, and 
the 100 ng/mL intermediate was prepared in the same way using 1 mL of the 1,000 ng/mL 
intermediate. 
 
The internal standards were prepared in a similar way by adding 1 mL of 8 deuterated analogs 
into a 10 mL volumetric flask, drying down to a third of the volume, adding the remaining 4 
compounds, and filling to the 10 mL line with 50% methanol in water solution to get a 10,000 
ng/mL intermediate, except for doxepin-d3, which was at a final concentration of 100,000 ng/mL 
since the starting concentrations of all the internal standard samples were at 100 ug/mL except 
for doxepin-d3 which was at one mg/mL. The internal standards at a concentration of 500 ng/mL 
were used throughout the experiment, and this was prepared by adding 250 uL of the 10,000 
ng/mL intermediate to a 5 mL volumetric flask and filling it to the 5 mL line with 50% methanol 
in water solution, then transferring the contents to a test tube and labeling it accordingly. All the 
working solutions were stored at -20oC in the freezer for the duration of the project. 
 
Calibrators and Quality Control Samples 
Seven calibration levels at 2.5, 5, 10, 50, 100, 500, and 900 ng/mL were prepared by spiking a 
known volume of working solution into 5 mL of blood. The 2.5, 5, and 10 ng/mL calibrators 
were prepared using the 1,000 ng/mL stock solution and spiking 12.5, 25, and 50 uL of it, 
respectively. The 50 and 100 ng/mL calibrators were prepared using the 10,000 ng/mL stock 
solution and spiking 25 and 50 uL of it, respectively. The 500 and 900 ng/mL calibrators were 
prepared using the 100,000 ng/mL stock solution and spiking 25 and 45 uL of it, respectively. 
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Quality Controls were prepared at the low, mid, and high range concentrations (5, 100, and 500 
ng/mL) as described for calibrators. 
 
Extraction Procedure 
Solid Phase Extraction (SPE) Cerex Trace-B (SPEware, Baldwin Park, CA) columns were 
conditioned with 1 mL methanol, and 1 mL of water using the Automated Liquid Dispenser 
(ALD) (SPEware, Baldwin Park, CA). Sample loading was done manually by adding a LEUR 
seal and pipetting 1 mL of pH 6 sodium phosphate buffer into the columns after conditioning, 
along with 50 uL of internal standard, and 300 uL of blood. The seal was removed and the 
columns were loaded back onto the ALD and washed with 3 mL of water, 3 mL of 0.1M acetic 
acid, and 3 mL of 25% methanol in water solution. The columns were dried with heated nitrogen 
for 14 minutes. The elution solvent, consisting of dichloromethane, isopropanol, and ammonium 
hydroxide (70:26:4) was prepared prior to elution. Seven hundred and fifty uL of the elution 
solvent was added to the columns and collected in vials that were dried in a concentrator to 
evaporate off the organic solvents. The dried eluents were reconstituted in 100 uL of mobile 
phase A (0.1% formic acid) and 10 uL were injected into the LC-MS/MS instrument. 
                                     
LC-MS/MS Instrumentation 
The instrument utilized in this project was an Agilent Triple Quadrupole Liquid Chromatograph 
Mass Spectrometer (Agilent Technology, Palo Alto, CA). Each drug was optimized to determine 
the best fragmentor voltage and collision energy that would yield the largest abundance of the 
fragments. Using the 1,000 ng/mL stock solution, the fragmentor voltage and collision energy 
were varied for each individual drug until the fragments appeared the most abundant. Two MRM 
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transitions were chosen for each drug. A cell accelerator voltage of 7 was used, at positive 
polarity (Table 1) 
 
      Table 1. Multiple Reaction Monitoring table for each drug 
Compound Name Precursor 
Ion (M+H) 
Fragmentor Product 
Ion 1 
Collison 
Energy 1 
Product 
Ion 2 
Collison 
Energy 2 
Amitriptyline 278.2 45 232.9 13 105.1 15 
Amitriptyline d3 281.2 70 105.1 10   
Bupropion 240.1 45 184 7 131.1 7 
Bupropion d9 249.2 80 185.1 10   
Citalopram 325.2 15 262.2 18 108.9 18 
Citalopram d6 331.2 50 108.8 22   
Clomipramine 315.2 50 86.1 22 58.1 22 
Cyclobenzaprine 276.2 25 231.2 14 216 14 
Desipramine 267.2 10 236.3 6 208.1 6 
Desipramine d3 270.3 10 75.1 6   
O-desmethylvenlafaxine 264.2 100 246.2 8 201.2 8 
Doxepin 280.2 40 235 16 107.4 20 
Doxepin d3 283.2 40 107.1 20   
Duloxetine 298.2 80 154 2 44.2 16 
Duloxetine d3 301.1 70 157.2 2   
Fluoxetine 310.1 70 148 2 44.1 2 
Fluoxetine d6 316.2 70 154.1 2   
Imipramine 281.2 110 235.9 12 208 14 
Imipramine d3 284.3 90 89.1 14   
Mirtazapine 266.2 30 209.1 16 195.1 16 
Nortripyline 264.2 105 233.3 16 117.2 24 
Nortripyline d3 267.3 30 117.1 16   
Paroxetine 330.2 110 283.7 16 192 16 
Paroxetine d6 336.2 110 198.5 34   
Sertraline 307.1 85 275.8 4 158.8 24 
Sertraline d3 309.1 80 275.1 4   
Trazodone 372.2 50 176.1 14 148.1 14 
Trimipramine 295.2 50 208.1 14 100.2 14 
Venlafaxine 278.2 65 147.2 18 121 20 
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The parameters used for the mass spectrometer, employing an electrospray ionization source, are 
as follows: gas temperature at 350°C, gas flow at 10 L/min, nebulizer pressure at 50 psi, sheath 
gas temperature at 400°C, sheath gas flow at 11 L/min, and capillary voltage of 4000 V. The 
chromatic separation was performed with a Kinetex Biphenyl 50 x 3.0 mm column at a 
temperature of 50°C with a gradient elution consisting of Mobile Phase A, 0.1% formic acid in 
water, and Mobile Phase B, 0.1% formic acid in acetonitrile. At a flow rate of 0.7 mL/min, the 
gradient started at 20% B and increased to 65% B at 1.80 minutes, then further increased to 75% 
B at 2.20 minutes. From 2.20 to 2.21 minutes, the gradient decreased from 75% to 20%.  
 
 
Method Validation 
Guidelines for method validation were obtained from procedures presented by the 
Scientific Working Group for Forensic Toxicology (Scientific Working Group for 
Forensic Toxicology (SWGTOX), 2013) as well as the guidelines used in the Cordant 
Laboratory. Accuracy and precision testing were performed by running the quality controls in 
triplicate (intraday) for a single day’s analysis, and over five days (interday) for analysis over 
five days, to analyze deviations. Accuracy, or bias, compares the measured value with the 
accepted value. Precision measures the closeness of a series of measurements. Accuracy is 
reported as a percent difference, and precision is expressed as the coefficient of variation (%CV). 
A % difference of within 20% and a %CV of less than 15% was considered acceptable.  
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Linearity testing was performed by extracting and analyzing calibrators each day over five days 
using a weighted 1/x2 model. Linearity was considered acceptable if each calibration level was 
within 20% of the indicated concentration, and the r2 value for each curve was greater than 0.985. 
The LOQ was determined by testing decreasing concentrations that yielded 20% accuracy and 
precision. 
 
Matrix effects, analyte recovery, and process efficiency were tested using neat samples (A), pre-
extracted samples (B), and post-extraction samples (C). Three neat samples were prepared by 
spiking directly into the autosampler vials, drying off the methanol, and reconstituting with the 
mobile phase. The 15 pre-extraction samples were spiked prior to extraction, and the 15 post-
extraction samples were spiked after extraction. Fifteen uL of the 10,000 ng/mL working 
solution was spiked into 300 uL of different donor samples to obtain a concentration of 500 
ng/mL. The average response was used for the calculations. Matrix effect was calculated using 
the formula B-A/A*100%, analyte recovery was calculated using C/B*100%, and process 
efficiency was calculated using C/A*100%. 
 
Carryover was tested by running blanks after the highest calibrator (900 ng/mL), and the highest 
calibrator times 10 (9,000 ng/mL). Carryover was considered insignificant if the signal had a 
concentration lower than half that of the LOQ. Dilution integrity testing was performed by 
diluting the upper limit calibrator in a 1:2, 1:5, and 1:10 ratio with negative blood from the blood 
pool. The concentrations of the diluted samples were compared to their expected concentration 
values and were considered acceptable if they were quantified within 20%. 
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Selectivity and specificity testing were performed to assess endogenous and exogenous 
interferences. For selectivity, 15 blank samples, in which no drugs or internal standards were 
added, were analyzed, along with 15 samples in which just the drugs were added without the 
internal standard, and 15 samples in which just the internal standards were added. For specificity, 
10 samples were spiked at the lowest calibrator level and common antipsychotic drugs were 
added at the highest calibrator level, to assess the effects of exogenous interferences on the 
detection and quantification of the antidepressants. Antidepressants and antipsychotics are often 
prescribed together for long term treatment of some mental health disorders such as 
schizophrenia and bipolar disorder and are therefore found together in a lot of authentic donor 
samples. Exogenous interferences were also tested by spiking blank samples with just the 
antipsychotic drugs at the highest concentration to see if any peaks were present. Any 
interferences were considered insignificant if the concentration of the signal was below that of 
the lowest calibrator level. Autosampler stability was evaluated by reinjecting 3 quality control 
samples (low, medium, and high) for three consecutive days, leaving them in the autosampler for 
the entire period at room temperature. Samples were considered stable in the autosampler if the 
calculated concentrations were within 20% of their initial concentration. 
 
Authentic blood specimens testing was performed using positive authentic donor samples 
provided by Cordant Laboratory (n=10). For the few drugs that were not present in the donor 
samples and could not be quantified, three blank samples were spiked with the drug at 
concentrations of 200, 100, and 25b ng/mL by a lab member for blind proficiency testing. These 
tests were performed to assess the efficiency of the validated method in detecting the drugs in 
real donor sample matrices.
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Results 
 
The intra-day and inter-day accuracy and precision results are listed below in Table 2 for each 
drug. The accuracy values generally fell within 20% and the precision values generally fell 
within 15%. The few outliers were mostly confined to the lower concentration quality controls 
and were only outside the acceptable range on certain days, rather than across all five days. O-
desmethylvenlafaxine yielded a 49% and 27.4% difference in intra-day accuracy on day 5 for the 
5 and 100 ng/mL quality controls, respectively, and a 23.7% interday CV for the 5 ng/mL quality 
control. Duloxetine yielded a 41.4% difference in intraday accuracy on day 3 for the 5 ng/mL 
quality control, and a 19.5% intraday CV on day 1. Mirtazapine yielded a 27.6% difference in 
intraday accuracy on day 3 for the 5 ng/mL quality control. Paroxetine yielded a 24% difference 
in intraday accuracy on day 5 for the 5 ng/mL quality control. Sertraline yielded a 22.1% 
difference in intraday accuracy on day 2 for the 5 ng/mL quality control.  
                        Table 2. Accuracy and Precision results for each drug (n=15) 
Drug Conc. 
(ng/mL) 
Accuracy  Precision (%CV) 
Intra-day 
(n=3) 
Inter-
day 
(n=15) 
Intra-day 
(n=3) 
Inter-
day 
(n=15) 
 
Amitriptyline 
5 3.63-16.0 11.6 0.24-4.23 4.51 
100 0.59-4.90 1.35 0.66-5.15 2.94 
500 0.68-9.35 1.29 2.12-4.39 5.13 
 
Bupropion 
5 0.11-8.51 4.10 1.03-5.93 3.11 
100 0.40-8.60 4.91 0.48-1.37 3.62 
500 1.48-8.73 4.46 0.63-2.04 3.59 
 
Citalopram 
5 3.41-13.8 7.56 1.72-4.89 3.94 
100 0.20-7.49 2.98 0.95-3.06 3.34 
500 2.15-4.81 2.63 0.77-2.92 2.81 
 
Clomipramine 
5 3.60-27.0 10.3 0.40-4.85 9.97 
100 0.59-8.29 0.32 0.24-1.80 5.00 
500 1.43-4.06 0.38 1.01-2.08 3.20 
 
Cyclobenzaprine 
5 1.94-18.3 10.8 0.88-6.01 5.55 
100 1.60-5.52 0.69 0.97-1.63 4.12 
500 1.73-11.8 6.82 1.08-2.93 4.05 
 
Desipramine 
5 6.82-14.4 11.2 1.81-3.56 2.73 
100 0.14-5.67 2.89 0.86-2.25 3.22 
500 0.93-2.58 0.05 0.49-1.48 1.95 
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O-desmethyl-
venlafaxine 
5 0.62-49.0 15.1 0.78-2.90 23.7 
100 1.49-27.4 13.8 0.83-1.42 9.03 
500 0.09-17.4 8.16 0.69-1.39 6.92 
 
Doxepin 
5 3.06-15.7 4.81 1.26-7.25 7.66 
100 1.27-7.21 3.30 0.56-5.07 3.45 
500 0.09-4.81 0.12 0.10-2.82 2.78 
 
Duloxetine 
5 1.57-41.4 17.4 3.31-19.5 15.9 
100 1.23-13.2 4.21 1.56-10.0 7.57 
500 1.82-7.54 3.34 2.08-9.83 3.61 
 
Fluoxetine 
5 7.67-19.0 13.2 2.05-8.74 3.55 
100 0.70-6.91 3.61 1.17-3.89 3.63 
500 0.33-5.61 0.38 1.10-1.91 3.99 
 
Imipramine 
5 6.25-12.0 9.05 0.98-3.18 2.60 
100 0.25-5.38 1.82 0.15-0.90 3.40 
500 0.27-2.60 0.46 0.44-1.11 1.68 
 
Mirtazapine 
5 2.41-27.6 6.20 5.46-13.7 15.5 
100 1.61-19.1 4.73 1.02-3.09 10.8 
500 0.28-14.5 3.38 1.11-3.47 6.74 
 
Nortriptyline 
5 3.81-13.8 8.47 1.23-7.01 3.48 
100 0.36-8.06 3.03 0.30-1.50 4.74 
500 0.11-4.42 1.48 1.73-3.17 1.91 
 
Paroxetine 
5 1.69-24.0 17.1 1.67-4.78 11.6 
100 0.09-3.50 0.76 3.19-8.99 2.17 
500 0.60-12.5 1.13 4.06-11.6 8.18 
 
Sertraline 
5 6.77-22.1 11.2 6.25-14.6 5.69 
100 1.73-12.0 6.99 2.62-7.27 3.48 
500 1.37-8.00 3.33 1.18-5.70 3.22 
 
Trazodone 
5 1.42-21.9 6.81 0.73-8.81 16.5 
100 2.84-17.7 1.58 1.28-2.21 11.8 
500 0.30-16.2 5.42 0.55-2.04 6.58 
 
Trimipramine 
5 3.80-9.54 7.09 1.79-2.62 1.99 
100 1.15-6.26 2.15 0.18-1.53 4.27 
500 0.77-5.64 2.03 0.48-2.32 3.04 
 
Venlafaxine 
5 1.40-10.2 5.59 0.23-2.71 3.43 
100 2.40-4.78 1.06 0.08-0.71 4.11 
500 1.03-8.85 4.96 0.17-0.98 3.08 
 
 
Each calibration curve for each individual drug met the criteria for linearity validation testing. 
The linear range was 2.5-900 ng/mL. The coefficient of determination for all the curves using the 
weighted inverse square model was greater than 0.985, with a range of 0.989-0.999. The percent 
error for each calibration level was within 20% for all drugs. Table 3 lists the coefficient of 
determination, slope, and intercept of all the drugs.  
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                   Table 3. Coefficient of variation, slope, and intercept of the linear curves for each drug (n=15) 
Drug Coefficient 
of Variation 
Slope Intercept 
Amitriptyline 0.999 17.5 -0.0195 
Bupropion 0.998 3.75 -0.0021 
Citalopram 0.999 4.20 -0.0010 
Clomipramine 0.997 28.9 -0.0229 
Cyclobenzaprine 0.997 15.3 0.0009 
Desipramine 0.999 5.82 -0.0017 
O-desmethylvenlafaxine 0.989 2.39 0.0008 
Doxepin 0.998 1.32 -0.0007 
Duloxetine 0.997 5.81 -0.0083 
Fluoxetine 0.999 6.11 -0.0019 
Imipramine 0.999 2.77 -0.0003 
Mirtazapine 0.997 4.89 0.0004 
Nortriptyline 0.998 8.76 -0.0010 
Paroxetine 0.997 72.2 0.0004 
Sertraline 0.991 0.67 0.0004 
Trazodone 0.997 16.5 0.0084 
Trimipramine 0.999 86.8 -0.0368 
Venlafaxine 0.999 1.62 -0.0007 
 
 
The LOQ for all the drugs was 2.5 ng/mL. The chromatograms of each drug at the LOQ are 
shown below in Figure 1. Doxepin’s unique peak shape is due to the mixture of cis and trans 
isomers (in a 15:85 ratio in prescribed medication as well as the Cerilliant standards); the method 
separates the two to a certain extent, resulting in the smaller peak adjacent to the larger peak. 
 
 
                                                      
                                                  Amitriptyline                                             Bupropion     
 
                                          
                                             Citalopram                                                                             Clomipramine 
 
 
                              Cyclobenzaprine                                                                        Desipramine      
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                                            Trimipramine                                                                      Venlafaxine 
        
 
Figure 1. chromatograms of the drugs at LOQ (2.5 ng/mL) 
 
 
The matrix effect, recovery, and efficiency were evaluated for each drug, along with the %CV 
for the pre-extraction and post-extraction samples. The results are shown in Table 4 below. Most 
of the drugs exhibited ion enhancement, from a 1.53% ion enhancement for clomipramine to a 
79.4% ion enhancement for mirtazapine. Duloxetine, paroxetine, and sertraline on the other hand, 
exhibited ion suppression. Duloxetine exhibited a 13.8% ion suppression, paroxetine exhibited a 
15.1% ion suppression, and sertraline exhibited a 38.6% ion suppression. There were no 
significant problems with recovery for all the drugs, with bupropion yielding the lowest recovery 
(84.7%) of all the antidepressants tested. The overall process efficiency was high for this method, 
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with sertraline yielding the lowest efficiency of 62.7%. Comparing the calculated concentration 
to the expected concentrations, the %CV was generally lower for the post-extraction samples 
than the pre-extraction samples, since the extraction process could not affect the concentration of 
the drugs in the post-extraction samples. 
 
             Table 4. Matrix effect, recovery, efficiency, and %CV for each drug (n=15) 
Drug  Matrix  
Effect (%) 
Recovery 
(%) 
Efficiency 
(%) 
% CV (n=15) 
Pre Post 
Amitriptyline 26.4 111 140 27.6 16.0 
Bupropion 9.58 84.7 92.8 69.5 70.1 
Citalopram 46.4 120 175 23.9 13.5 
Clomipramine 1.53 117 119 41.4 28.0 
Cyclobenzaprine 24.7 110 138 22.4 12.2 
Desipramine 12.5 121 136 27.4 12.8 
O-desmethylvenlafaxine 77.4 104 184 10.8 11.5 
Doxepin 42.3 113 161 24.4 14.2 
Duloxetine -13.8 115 99.5 40.2 24.2 
Fluoxetine 2.19 113 115 37.4 23.1 
Imipramine 32.5 112 148 17.8 9.74 
Mirtazapine 79.4 109 195 12.9 12.9 
Nortriptyline 5.12 117 123 35.2 18.6 
Paroxetine -15.1 122 103 44.1 24.0 
Sertraline -38.6 102 62.7 62.5 46.0 
Trazodone 75.9 100 176 8.55 12.7 
Trimipramine 23.5 115 142 31.4 16.6 
Venlafaxine 60.2 107 171 11.2 11.1 
 
 
No significant carryover was detected for all the drugs, as the blank sample chromatograms 
shown in Figure 2 below show peaks below the LOQ. For each antidepressant, the 
chromatogram on the left was run after an injection at 900 ng/mL, and the chromatogram on the 
right was run after an injection at 9000 ng/mL.  
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Figure 2. Chromatograms for each drug (n=15) from carryover testing 
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The highest calibrator level was used to perform a series of dilutions to ensure dilution integrity. 
For each drug, the percent difference was calculated for each dilution. The percent error 
averaged 12.8% for the 1:2 dilutions. For the 1:5 and 1:10 dilutions, with percent errors 
averaging 16.4% and 29.1% respectively, there were variations for each drug, with some 
showing a very small percent error such as 0.55% for doxepin and some showing a percent error 
as great as 84%, such as clomipramine. Due to these variances, dilution integrity was not 
maintained for the 1:5 and 1:10 dilutions. However, some drugs exhibited high dilution integrity 
across all the dilutions. Cyclobenzaprine showed a percent error of 0.32%, 4,44%, 6.08%, and 
13.4% for the 1:1, 1:2, 1:5, and 1:10 dilutions. Similarly, imipramine showed a percent error of 
3.12%, 0.8%, 11.2%, and 1.64% for the series of dilutions, and venlafaxine showed a percent 
error of 0.44%, 7.28% 1.88%, and 8.6% for the series of dilutions. On the other hand, some 
drugs could not maintain dilution integrity. Citalopram showed a percent error of 4.09%, 16.1%, 
29.7%, and 42.1% for the 1:1, 1:2, 1:5, and 1:10 dilutions, and clomipramine showed a percent 
error of 3.27%, 23.2%, 29.4%, and 84.1% for the series of dilutions. 
 
 
For selectivity validation testing, 15 negative donor samples were analyzed without the addition 
of the antidepressants or internal standard, to see if there were any interferences present in the 
matrix. As shown in Figure 3 below, no significant peaks were found for both the drug and 
internal standard chromatograms. The peaks were below the LOQ and at insignificant retention 
times. 
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Figure 3. No drug (left) and no internal standard (right) peaks are shown for each drug (n=15) 
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The same 15 negative donor samples were analyzed, this time with just the addition of the 
antidepressants. As shown in Figure 4 below, there is a peak indicating the drug is present, and 
some small peaks with insignificant concentrations and retention times in the internal standard 
chromatogram.  
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Figure 4. Drug (left) and no internal standard (right) peaks are shown for each drug (n=15) 
 
 
Similarly, the same 15 samples were analyzed again this time with the addition of just the 
internal standard. As shown in Figure 5 below, there are no significant signals for the drug and a 
peak indicating the presence of the internal standard. 
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Figure 5. No drug (left) and internal standard (right) peaks are shown for each drug (n=15) 
 
 
For specificity testing, the effects of other commonly used drugs on the detection and 
quantification of the antidepressants in blood was assessed using 10 samples that were spiked 
with the antidepressants at LOQ along with a high concentration of an antipsychotic panel. The 
calibrators were all within the acceptable range of 20%, and there were no additional peaks that 
were detected other than the peaks for the antidepressants.  Similarly, exogenous interferences 
were also tested on negative donor samples by spiking the samples with just an antipsychotic 
panel in high concentrations. As shown in Figure 6 below, there are no significant peaks 
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indicating the antidepressants are present, except for the chromatograms for bupropion, 
citalopram, fluoxetine, and trimipramine, which depict peaks at similar retention times to the 
antidepressants but at concentrations lower than the LOQ.  
 
 
Figure 6. Exogenous interferences for all drugs (n=15) 
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Authentic sample testing was performed using positive donor samples. In Figure 7 below, a 
distinct amitriptyline peak is shown in donor sample 4 at a concentration of 42.19 ng/mL. In 
Figure 8, a cyclobenzaprine peak is shown in donor sample 7 at a concentration of 14.76 ng/mL. 
In Figure 9, a citalopram peak is shown in donor sample 9 at a concentration of 492.7 ng/mL. 
The concentrations of these drugs were not listed for the positive donor samples, so blind 
proficiency testing was performed. The results all fell within the accepted 20% range (Table 5).  
 
 
 
Figure 7. Amitriptyline detected in donor sample 4 
 
  Figure 8. Cyclobenzaprine detected in donor sample 7 
 
Figure 9. Citalopram detected in donor sample 9 
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                                             Table 5. blind proficiency testing for each drug (n=15) 
Drug Sample Percent 
Error (%) 
 
Amitriptyline 
ADB 1 2.08 
ADB 2 10.1 
ADB 3 14.9 
 
Bupropion 
ADB 1 14.1 
ADB 2 2.34 
ADB 3 8.51 
 
Citalopram 
ADB 1 0.33 
ADB 2 6.66 
ADB 3 4.49 
 
Clomipramine 
ADB 1 8.87 
ADB 2 1.04 
ADB 3 13.3 
 
Cyclobenzaprine 
ADB 1 8.15 
ADB 2 9.52 
ADB 3 5.98 
 
Desipramine 
ADB 1 1.81 
ADB 2 12.6 
ADB 3 4.96 
 
O-desmethylvenlafaxine 
 
ADB 1 2.06 
ADB 2 5.07 
ADB 3 3.68 
 
Doxepin 
ADB 1 2.48 
ADB 2 10.7 
ADB 3 9.33 
 
Duloxetine 
ADB 1 7.93 
ADB 2 5.47 
ADB 3 5.54 
 
Fluoxetine 
ADB 1 0.31 
ADB 2 12.2 
ADB 3 16.5 
 
Imipramine 
ADB 1 4.22 
ADB 2 8.21 
ADB 3 10.3 
 
Mirtazapine 
ADB 1 8.52 
ADB 2 8.82 
ADB 3 9.58 
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Nortriptyline 
ADB 1 2.47 
ADB 2 14.8 
ADB 3 11.1 
 
Paroxetine 
ADB 1 2.45 
ADB 2 2.38 
ADB 3 2.84 
 
Sertraline 
ADB 1 4.16 
ADB 2 3.86 
ADB 3 5.34 
 
Trazodone 
ADB 1 5.61 
ADB 2 6.84 
ADB 3 3.57 
 
Trimipramine 
ADB 1 0.39 
ADB 2 8.67 
ADB 3 12.7 
 
Venlafaxine 
ADB 1 8.94 
ADB 2 4.32 
ADB 3 9.62 
 
 
Autosampler stability results showed no indication of analyte instability over the three days that 
the samples were in the autosampler at room temperature. Results throughout all three days 
demonstrated a percent difference of below 15%.  
 
Discussion 
A method was developed and validated for the detection and quantification of 18 antidepressants 
in whole blood. The samples were extracted using solid phase extraction, and analyzed using 
LC-MS/MS. The LOQ for this method was 2.5 ng/mL, and the calibration range was 2.5-900 
ng/mL using 300 uL of the sample. In Montenarh et al. (2014)’s quantification method for 33 
antidepressants using 500 uL of sample for liquid-liquid extraction and LC-MS/MS, their LOQ 
varied from 3-300 ng/mL for their 33 antidepressants. Castaing et al. (2007) developed a similar
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method for antidepressants utilizing the LC-MS/MS with liquid-liquid extraction. However, their 
study only involved eight antidepressants with a LOQ of 5 ng/mL and a linear range of 5-500 
ng/mL. Both studies required 500 uL of sample. In this current project, less sample (300 uL) was 
used and solid-phase extraction was used instead of liquid-liquid extraction due to its easy 
automation, high selectivity, reduced solvent usage, and no emulsions. Also, in Castaing et al. 
(2007)’s study, only one internal standard, methylrisperidone, was used. Similarly, in Montenarh 
et al. (2014)’s method, one universal stable-isotope-labeled internal standard was used to save 
time and resources. They acknowledged that the number of analytes that failed their validation 
criteria could have been reduced by using more than one internal standard. In Nielson and 
Johansen (2012)’s method for 25 common drugs in whole blood (7 of which were 
antidepressants) using liquid-liquid extraction and ultra performance LC-MS/MS with 0.10 g of 
sample at an LOQ range from 2-10 ng/mL, they came to the conclusion that one of their 
proficiency tests for citalopram failed because they were not able to obtain citalopram-d6 as an 
internal standard. In this present study, 12 deuterated analogs of the antidepressants were 
included in the internal standard panel. This made it easier to determine which internal standard 
worked best for each antidepressant during analysis.  
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Accuracy and precision testing were performed over five days using triplicates of each quality 
control sample. The results were similar to Nielson and Johansen (2012)’s results, in which they 
used 2 MRM transitions as well, and four replicates over two days. Their results for recovery of 
each drug were in the 68-94% range using their method. In this present study, bupropion yielded 
the lowest recovery of 84.7%. In Wille et al. (2005)’s method for 13 antidepressants extracted 
via solid phase extraction and analyzed with GCMS, trazodone yielded a recovery of 39%, while 
the other drugs were within the 70-109% range. They performed HPLC analysis and found that 
trazodone yielded higher recovery, so the problem lay within the GCMS method. In this present 
study, o-desmethylvenlafaxine was found to have the greatest matrix effect, at 77.4%. Most of 
the drugs in this study exhibited ion enhancement; however, they all passed the linearity, 
accuracy, and precision validation criteria with no particular problems. Moreover, carryover and 
dilution integrity validation testing results were absent in Montenarh et al. (2014)’s study. 
Carryover testing is important in order to ensure that no remnants of the previous analyte is 
carried over into the next run, since labs typically run a large number of analytes back to back on 
the same instrument. In this present study, no carryover was detected after blanks were run right 
after a 900 ng/mL and 9,000 ng/mL sample. Dilution integrity testing is also important when it 
comes to instances in a lab where the sample might be too concentrated and dilution is necessary. 
This present study performed several different dilutions and assessed each drug’s closeness in 
concentration to the expected. All the drugs performed as expected when they were diluted in a 
1:2 ratio. For the 1:5 and 1:10 dilutions, some drugs had higher percent error than other drugs, 
showing variation. Montenarh et al. (2014)’s method also attempted to cross-calibrate between 
whole blood, plasma, and serum and they came to the conclusion that calibration should be 
performed in the same matrix; otherwise, especially for whole blood, significant differences have 
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to be considered and the clinical or forensic interpretation would be invalid. This present study 
focused on whole blood since this matrix is preferred for accurate determination of drug 
concentration due to the correlation between drug concentrations in blood and impairment. This 
is also why blood is the preferred matrix for therapeutic drug monitoring. In most laboratories, 
blood and urine are the most common specimens that they receive, so a fast, reliable, and 
reproducible method in blood as a matrix is necessary. The autosampler stability testing 
indicated no instability for all the antidepressants at room temperature over 3 days. Anand and 
Bansal (2010) conducted a degradation study on mirtazapine in particular, and found that it was 
stable at temperatures of up to 50°C, while Bishop-Freeman et al., (2018) studied the degradation 
of bupropion over 50 days and found that the rate of degradation was most dramatic for room 
temperature samples. The interpretation of postmortem bupropion is often a challenge to the 
forensic toxicology community because of the instability of the parent compound; the metabolite, 
threobupropion, was found to be more stable over the 50 day stability study. However, the 
decrease in concentration of bupropion for the first 3 days of the study was reported as 
insignificant, so accurate detection and quantification analyses can be made for the 18 
antidepressants for up to 3 days at room temperature. 
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Conclusion 
 
A method for the detection and quantification of 18 antidepressants in whole blood has been 
successfully developed and validated. The method has proven to be sensitive and specific, 
requiring only 300 uL of blood to achieve 2.5 ng/mL LOQ. This project can guide further 
research into a wider array of antidepressants, and possibly different categories of drugs, along 
with various other biological matrices.  
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